Showing results (21-30 of 374) with videos related to
Sort By:
Pageof 38
Breast Cancer Research and Treatment|May 22, 2010
Should bisphosphonates be utilized in the adjuvant setting for breast cancer?Allan LiptonExpert Opinion on Emerging Drugs|December 10, 2003
Bisphosphonate therapy in the oncology settingAllan LiptonExpert Review of Anticancer Therapy|August 3, 2011
Zoledronic acid: multiplicity of use across the cancer continuumAllan LiptonCurrent Opinion in Supportive and Palliative Care|August 8, 2008
RANKL inhibition in the treatment of bone metastasesAllan Lipton, Susie JunBJU International|October 18, 2005
Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancersFred Saad, Allan LiptonBone|October 19, 2010
Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasisAllan Lipton, Carsten GoesslExpert Review of Clinical Pharmacology|September 5, 2012
Denosumab for the treatment of cancer therapy-induced bone loss and prevention of skeletal-related events in patients with solid tumorsAllan Lipton, Arun BalakumaranSeminars in Oncology|November 30, 2010
Antitumor effects and anticancer applications of bisphosphonatesGareth Morgan, Allan LiptonCancer Treatment Reviews|December 18, 2009
SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancerFred Saad, Allan LiptonCurrent Opinion in Supportive and Palliative Care|May 22, 2010
Bone-marker levels in patients with prostate cancer: potential correlations with outcomesFred Saad, Allan LiptonPageof 38